Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership1,291,726 shares
Latest Disclosed Value $ 427,393,317
Invesco Ltd. reports 40.36% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 1,291,726 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $369,046,118 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 2,165,840 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -40.36% during the quarter. The current value of the position is $325,256,607 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,291,726 -874,114 -40.36 427,393 -50.38 0.0081
2026-02-19 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,165,840 683,998 46.16 861,246 27.46 0.1321
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,481,842 140,148 10.45 675,720 54.45 0.1065
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,341,694 427,902 46.83 437,513 77.32 0.0744
2025-05-12 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 913,792 355,302 63.62 246,742 87.75 0.0467
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 558,490 -137,378 -19.74 131,418 -31.33 0.0243
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 695,868 303,027 77.14 191,385 100.49 0.0370
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 392,841 214,528 120.31 95,460 258.23 0.0202
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 178,313 1,453 0.82 26,649 -21.28 0.0057
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 176,860 -39,709 -18.34 33,853 -11.74 0.0081
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 216,569 -173,558 -44.49 38,354 -48.24 0.0103
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 390,127 22,752 6.19 74,101 0.69 0.0194
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 367,375 -302,474 -45.16 73,593 -53.77 0.0205
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 669,849 -67,981 -9.21 159,190 7.79 0.0466
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 737,830 568,999 337.02 147,685 499.74 0.0475
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 168,831 -799,924 -82.57 24,625 -84.43 0.0075
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 968,755 78,665 8.84 158,187 4.80 0.0403
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 890,090 -164,082 -15.57 150,942 -24.16 0.0364
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,054,172 52,271 5.22 199,039 17.19 0.0504
2021-08-17 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,001,901 -214,202 -17.61 169,841 -1.08 0.0418
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,216,103 -62,139 -4.86 171,702 3.35 0.0458
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,278,242 183,591 16.77 166,133 4.24 0.0484
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,094,651 -30,044 -2.67 159,380 -4.32 0.0539
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,124,695 385,249 52.10 166,579 106.96 0.0596
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 739,446 161,316 27.90 80,488 20.88 0.0339
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 578,130 34,648 6.38 66,584 52.34 0.0207
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 543,482 46,934 9.45 43,707 21.31 0.0114
2019-08-14 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 496,548 289,314 139.61 36,030 86.05 0.0093
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 496,548 259,050 36,030
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 207,234 189,786 1,087.72 19,366 1,422.48 0.0065
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,448 2,940 20.26 1,272 0.16 0.0005
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,508 -118,362 -89.08 1,270 -90.29 0.0004
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 132,870 77,140 138.42 13,086 97.17 0.0043
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,730 -16,675 -23.03 6,637 -27.85 0.0025
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,405 -8,473 -10.48 9,199 -3.19 0.0033
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 80,878 51,678 176.98 9,502 307.99 0.0035
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,200 -140,948 -82.84 2,329 -73.29 0.0007
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 170,148 14,715 9.47 8,720 49.85 0.0029
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 155,433 41,667 36.63 5,819 -24.54 0.0020
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 113,766 101,499 827.42 7,711 1,032.31 0.0026
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,267 -118,168 -90.60 681 -91.68 0.0003
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 130,435 -267,566 -67.23 8,188 -78.15 0.0033
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 398,001 -135,504 -25.40 37,468 -12.61 0.0150
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 533,505 -173,966 -24.59 42,873 -49.45 0.0182
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 707,471 177,724 33.55 84,805 53.31 0.0333
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 529,747 1,139 0.22 55,316 7.88 0.0214
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 528,608 12,628 2.45 51,275 27.24 0.0198
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 515,980 16,578 3.32 40,298 27.74 0.0161
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 499,402 499,021 130,976.64 31,547 131,345.83 0.0124
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 381 -56,130 -99.33 24 -99.34 0.0000
2013-11-13 2013-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 56,511 -105,677 -65.16 3,617 -28.06 0.0016
2013-08-14 2013-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 162,188 162,188 5,028 0.0023
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.